Blood dialysis therapy has long been synonymous with haemodialysis\n(HD), which is routinely performed at hospitals. However, kidney failure\npatients have alternative treatment options, namely Continuous\nAmbulatory Peritoneal Dialysis (CAPD).<\/p>\n
Tony Richard Samosir, Chairman of the Indonesian Kidney Disease\nPatient Community (KPCDI), stated that most newly diagnosed patients\nonly discover alternative therapies after years of undergoing HD.<\/p>\n
\u201cIn Indonesia, nearly 98 per cent of kidney failure patients go\ndirectly into haemodialysis, whilst other treatment options such as CAPD\nor transplantation are often not fully explained to patients. For us at\nKPCDI, this is not merely a matter of treatment methods, but a matter of\npatients\u2019 rights to obtain complete information and determine their own\ntreatment choices,\u201d Tony stated on Friday (14 March).<\/p>\n
Chronic kidney disease (CKD) is often called a silent killer because\nsymptoms are frequently undetectable in early stages. Approximately 90\nper cent of patients only become aware of their condition when it has\nreached an advanced stage requiring dialysis or transplantation. The\nnumber of chronic kidney failure sufferers in Indonesia was recorded at\napproximately 1.5 million patients in 2023 and is estimated to continue\nincreasing.<\/p>\n
Amidst this surge, dialysis therapy in Indonesia remains dominated by\nhaemodialysis, with 134,057 patients during the 2022\u20132024 period. The\nfinancing burden borne by BPJS Kesehatan has also increased from Rp6.5\ntrillion in 2019 to Rp11 trillion in 2024.<\/p>\n
Unlike HD, CAPD allows patients to conduct therapy independently at\nhome by introducing dialysate fluid through a catheter in the abdomen\nand replacing it three to four times daily. This therapy provides\ngreater flexibility for patients to maintain their activities.<\/p>\n
Although covered in the national health system with a tariff of Rp8\nmillion per month in accordance with Health Ministry Regulation Number 3\nof 2023, CAPD utilisation remains low. The government targets a minimum\nof 10 per cent of dialysis patients to use this method.<\/p>\n
Tony attributed the low utilisation of CAPD partly to insufficient\neducation regarding treatment options provided to patients from the\ninitial diagnosis. In several countries, he noted, patients are given\ndetailed explanations regarding various treatment options before\nundergoing dialysis.<\/p>\n
\u201cIn Malaysia, for example, patients are given detailed explanations\nregarding both haemodialysis (HD) and peritoneal dialysis (PD) options,\nso they can determine the most suitable therapy. Meanwhile, in\nIndonesia, similar education is not yet common,\u201d he said.<\/p>\n
He added that after a patient\u2019s condition stabilises following\nseveral rounds of haemodialysis, the option to consider CAPD as a\ncontinuation therapy is often no longer presented. Consequently, many\npatients continue with HD because it is the only method they are aware\nof.<\/p>\n
\u201cWe frequently hear the same phrase from patients: \u2018Why didn\u2019t I know\nabout CAPD from the beginning?\u2019 Many patients only become acquainted\nwith this therapy through patient communities, not from the healthcare\nsystem. This demonstrates that education regarding kidney failure\ntreatment options has not been comprehensively communicated to patients\nfrom the outset,\u201d he stated.<\/p>\n
He hopes that education regarding treatment options becomes part of\nthe standard of care for kidney failure patients so they can understand\nand determine the most suitable therapy for the long term.<\/p>\n
\u201cKidney failure patients will undergo this therapy for life.\nTherefore, patients should not merely be objects of treatment, but must\nbe subjects who understand and choose their own therapy,\u201d he\nconcluded.<\/p>", "url": "https:\/\/jawawa.id\/newsitem\/capd-therapy-a-new-hope-for-kidney-failure-patients-undergoing-dialysis-1773482033", "image": "" }, "sponsor": "Okusi Associates", "sponsor_url": "https:\/\/okusiassociates.com" }